Table 3 Symptom characteristics
| Â | Â | ME/CFS | Post COVID-19 condition |
|---|---|---|---|
Age of diagnosis (years [mean ± SD]) |  | 29.8 ± 12.48 | 50.60 ± 8.68 |
Disease duration (years [mean ± SD]) |  | 11.20 ± 3.56 | 0.56 ± 0.53 |
Infectious onset, N (%) | Â | 3 (60.0%) | 5 (100.0%) |
Cognitive difficulties | Yes | 5 (100.0%) | 5 (100.0%) |
No | 0 (0.0%) | 0 (0.0%) | |
Pain | Yes | 5 (100.0%) | 4 (80.0%) |
No | 0 (0.0%) | 1 (20.0%) | |
Sleep disturbances | Yes | 5 (100.0%) | 5 (100.0%) |
No | 0 (0.0%) | 0 (0.0%) | |
Sensory disturbances | Yes | 4 (80.0%) | 5 (100.0%) |
No | 1 (20.0%) | 0 (0.0%) | |
Immune disturbances | Yes | 4 (80.0%) | 5 (100.0%) |
No | 1 (20.0%) | 0 (0.0%) | |
Gastrointestinal disturbances | Yes | 3 (60.0%) | 4 (80.0%) |
No | 2 (40.0%) | 1 (20.0%) | |
Cardiovascular disturbances | Yes | 5 (100.0%) | 3 (60.0%) |
No | 0 (0.0%) | 2 (40.0%) | |
Respiratory disturbances | Yes | 2 (40.0%) | 4 (80.0%) |
No | 3 (60.0%) | 1 (20.0%) | |
Thermostatic instability | Yes | 1 (20.0%) | 2 (40.0%) |
No | 4 (80.0%) | 3 (60.0%) | |
Urinary disturbances | Yes | 1 (20.0%) | 1 (20.0%) |
No | 4 (80.0%) | 4 (80.0%) |